No connection

Search Results

RCEL vs TKNO

RCEL
AVITA Medical, Inc.
BEARISH
Price
$5.14
Market Cap
$157.4M
Sector
Healthcare
AI Confidence
85%
TKNO
Alpha Teknova, Inc.
BEARISH
Price
$2.91
Market Cap
$155.9M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
RCEL
--
TKNO
--
Forward P/E
RCEL
-25.69
TKNO
-7.46
P/B Ratio
RCEL
-9.43
TKNO
2.27
P/S Ratio
RCEL
2.2
TKNO
3.85
EV/EBITDA
RCEL
-4.61
TKNO
-16.07

Profitability

Gross Margin
RCEL
82.13%
TKNO
33.17%
Operating Margin
RCEL
-59.09%
TKNO
-41.16%
Profit Margin
RCEL
-67.85%
TKNO
-42.59%
ROE
RCEL
--
TKNO
-22.83%
ROA
RCEL
-39.06%
TKNO
-9.26%

Growth

Revenue Growth
RCEL
-4.3%
TKNO
7.8%
Earnings Growth
RCEL
--
TKNO
--

Financial Health

Debt/Equity
RCEL
--
TKNO
0.41
Current Ratio
RCEL
0.57
TKNO
4.58
Quick Ratio
RCEL
0.43
TKNO
3.44

Dividends

Dividend Yield
RCEL
--
TKNO
--
Payout Ratio
RCEL
0.0%
TKNO
0.0%

AI Verdict

RCEL BEARISH

RCEL presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying liquidity and solvency issues. The company exhibits negative shareholders' equity (Price/Book: -9.43) and a critical liquidity shortage with a current ratio of 0.57, indicating an inability to cover short-term obligations. Despite strong gross margins (82.13%) and bullish analyst targets, the fundamental trend is negative with shrinking revenue (-4.30%) and a consistent history of missing earnings estimates.

Strengths
Very high gross margins (82.13%) indicating strong product pricing power
Recent short-term price recovery (+28.8% over 6 months)
Strong analyst consensus (Strong Buy) with a target price of $8.60
Risks
Negative shareholders' equity (Price/Book -9.43) indicating insolvency risk
Severe liquidity risk with a current ratio of 0.57 and quick ratio of 0.43
Negative year-over-year revenue growth (-4.30%)
TKNO BEARISH

TKNO exhibits severe financial weakness with a Piotroski F-Score of 1/9, indicating critical operational deterioration. While the company maintains a strong liquidity buffer with a current ratio of 4.58 and low debt-to-equity (0.41), it is plagued by deep negative profit margins (-42.59%) and a completely bearish technical trend (0/100). There is a significant disconnect between the optimistic analyst target of $9.00 and the market's reality, evidenced by a 49.6% price decline over the last year. The lack of profitability and poor deterministic health scores make this a high-risk speculative play.

Strengths
Strong short-term liquidity (Current Ratio: 4.58)
Low leverage (Debt/Equity: 0.41)
Positive YoY EPS growth (+18.2%) despite remaining negative
Risks
Critical operational health (Piotroski F-Score: 1/9)
Severe negative profitability (Profit Margin: -42.59%)
Strong bearish technical momentum (Technical Trend: 0/100)

Compare Another Pair

RCEL vs TKNO: Head-to-Head Comparison

This page compares AVITA Medical, Inc. (RCEL) and Alpha Teknova, Inc. (TKNO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile